Form 4 for BIO BIO-RAD LABORATORIES, INC.
Accepted 2021-09-03 00:00:00 ET · period of report 2021-09-01 · accession 0001062993-21-008244 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2021-09-03 | 2021-09-01+ | BIO | Last Andrew J. | EVP, COO | M - OptEx | $206.23 | +2,902 | 2,184 | New | +$598.5K |
| DM | 2021-09-03 | 2021-09-01 | BIO | Last Andrew J. | EVP, COO | S - Sale+OE | $813.10 | -2,000 | 1,881 | -52% | -$1.63M |
| D | 2021-09-03 | 2021-09-02 | BIO | Last Andrew J. | EVP, COO | F - Tax | $825.77 | -448 | 1,736 | -21% | -$369.9K |
| DM | 2021-09-03 | 2021-09-01 | BIO | Last Andrew J. | EVP, COO | A - Grant | $0.00 | +5,064 | 2,532 | New | $0 |
| DM | 2021-09-03 | 2021-09-01+ | BIO | Last Andrew J. | EVP, COO | M - OptEx | $0.00 | -2,902 | 3,000 | -49% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Bio-Rad A Common Stock | 2021-09-01 | M | A | 2,000 | $299.24 | 3,281.92 | D | — | — | (F1) Includes 13.9278 shares acquired under the Bio-Rad Employee Stock Purchase Plan on 06/30/2021. |
| 2 | Common | Bio-Rad A Common Stock | 2021-09-01 | S | D | 750 | $812.27 | 2,531.92 | D | — | — | (F2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $811.70 to $812.69, inclusive. The reporting person undertakes to provide to Bio-Rad Laboratories, Inc., any security holder of Bio-Rad Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 3 | Common | Bio-Rad A Common Stock | 2021-09-02 | F | D | 448 | $825.77 | 1,735.92 | D | — | — | |
| 4 | Common | Bio-Rad A Common Stock | 2021-09-01 | S | D | 599 | $814.09 | 1,281.92 | D | — | — | (F4) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $814.02 to $814.11, inclusive. The reporting person undertakes to provide to Bio-Rad Laboratories, Inc., any security holder of Bio-Rad Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 5 | Common | Bio-Rad A Common Stock | 2021-09-02 | M | A | 902 | $0.00 | 2,183.92 | D | — | — | (F5) Shares of Class A common stock acquired on the vesting of restricted stock units. |
| 6 | Common | Bio-Rad A Common Stock | 2021-09-01 | S | D | 651 | $813.15 | 1,880.92 | D | — | — | (F3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $812.71 to $813.34, inclusive. The reporting person undertakes to provide to Bio-Rad Laboratories, Inc., any security holder of Bio-Rad Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 7 | Derivative | Restricted Stock Units | 2021-09-01 | A | A | 2,532 | $0.00 | 2,532 | D | $0.00 · — to — | 2,532 Bio-Rad A Common Stock | (F6) Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. (F7) The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant. |
| 8 | Derivative | Restricted Stock Units | 2021-09-02 | M | D | 902 | $0.00 | 2,708 | D | $0.00 · — to — | 902 Bio-Rad A Common Stock | (F6) Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. (F10) On September 2, 2020, the reporting person was granted 3,610 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. |
| 9 | Derivative | Non-Qualified Stock Option (right to buy) | 2021-09-01 | M | D | 2,000 | $0.00 | 3,000 | D | $299.24 · — to 2029-04-29 | 2,000 Bio-Rad A Common Stock | (F9) The option, representing a right to purchase a total of 5,000 shares, became exercisable in five equal annual installments beginning on April 29, 2020, which was the first anniversary of the date on which the option was granted. |
| 10 | Derivative | Non-Qualified Stock Option (right to buy) | 2021-09-01 | A | A | 2,532 | $0.00 | 2,532 | D | $814.95 · — to 2031-09-01 | 2,532 Bio-Rad A Common Stock | (F8) The stock option vests over four years at 25% per year on the yearly anniversary date of the grant. |